Forgot password?
   Please leave this field empty
Support Education Research
Please leave this field empty
 

Click to jump to a state

Arizona | California | Colorado | Connecticut | District of ColumbiaIllinois | Louisiana | Maryland
Massachusetts | Michigan | Minnesota | New HampshireNew Jersey | New York | North Carolina
Ohio | Pennsylvania | South Carolina | TennesseeTexas | Washington | Wisconsin


 

(Arizona)

Mayo Clinic Arizona
13400 E. Shea Blvd.
Scottsdale, AZ 85259

Contact Information for Appointments

Central Appointment Office (self-referred)
Phone: 480-301-8484 / 800-446-2279 Fax: 480-301-6780

Referring Physician Services (physician referred)
Phone: 480-301-7085 / 866-629-6362 Fax: 480-301-4071

Division of Rheumatology
Phone: 480-301-8368 (Appointment Information)
Records fax: 480-301-9066

Clinic hours: Monday - Friday 7:30 a.m. to 5 p.m.

Mayo Clinic’s Campus in Arizona Patient and Visitor Guide    
https://www.mayoclinic.org/patient-visitor-guide/arizona

Becoming a Patient at Mayo Clinic’s Campus in Arizona       
https://www.mayoclinic.org/patient-visitor-guide/arizona/becoming-a-patient

#1 Hospital in Arizona - Mayo Clinic                                       
 https://www.mayoclinic.org/arizona

Mayo Clinic's core and primary value is the needs of the patient come first.  Mayo Clinic is recognized for serving the needs of patients with serious and complex diseases. At the Mayo Clinic in Arizona Scleroderma program rheumatologists work in a team environment to provide state-of-the-art diagnosis and treatment tailored to the individual with newly diagnosed or established illness. For patients attending the program long distance, their initial appointment with Rheumatology and consultations with the program’s multidisciplinary team and testing are typically accomplished for more complex illness in less than 5 days rather than weeks or months.

The Mayo Clinic in Arizona Scleroderma program is pleased to announce its 2019 endowment by the James C. and Norma I. Smith Foundation bringing together the art of care with the science of medicine in serving the needs of patients with scleroderma.  Please watch for Mayo Clinic in Arizona site specific clinical trials commencing in 2019 aimed at accelerating the discovery of new treatments for scleroderma.

 

Tuscon

Banner University Medical Center
3838 N. Campbell Ave., Bldg 2
Clinic F
Tucson, AZ 85719

https://deptmedicine.arizona.edu/divisions/pulmonary-allergy-critical-care-and-sleep-medicine
https://deptmedicine.arizona.edu/divisions/rheumatology

Clinic hours:  Monday - Friday 8 a.m. - 4:30 p.m.

Director:  Sachin Chaudhary, M.D.
Interstitial Lung Disease Program

Research Coordinators:  Heidi E. Erickson B.S.N., R.N.; Valerie R. Bloss, M.P.H.; Maria Gordon, M.S.

Physicians Affiliated with this Center:

Interstitial Lung Disease Program: (Appointments: (520) 694-3730)
Sachin Chaudhary, M.D.; Bhupinder Natt, M.D.; Kenneth S. Knox, M.D.; Tammer Y. El Aini, M.D.

Rheumatology: (Appointments: (520) 694-4000)
C. Kent Kwoh, M.D.; Shariq I. Chudhri, D.O.; Sabina Mian, M.D.; Dominik G. Sudano, M.D.; Ernest R. Vina, M.D.; M.S.

Pulmonary Hypertension Program:  Franz Rischard, D.O.

Lung Transplantation Program:  Steven R. Knoper, M.D.; Joshua Malo, M.D.; Sachin Chaudhary, M.D.; Bhupinder Natt, M.D.

Gastroenterology:  Hemanth Gavini, M.D.

GI Surgery:  Iman Ghaderi, M.D., M.Sc., F.R.C.S.C., F.A.C.S.

Dermatology:  Caroline A. Bangert, M.D.

Hand Surgery:  Tolga Turker

Thoracic Radiology:  Veronica Arteaga, M.D.; Diana Palacio, M.D.; Kavitha Yaddanapudi, M.D.

Nephrology:  Bijin Thajudeen, M.D.

Current Clinical Trials:

Studies Status
A multi-center, randomized, bouble-blinded, placebo-controlled trial to evaluate the safety and efficacy on inhaled Trepostinil in subjects with pulmonary hypertension due to parenchymal lung disease.  Active
Comprehensive phenotypic characterization of patients with scleroderma associated interstitial lung Disease and pulmonary hypertension.  Active
Efficacy and safety of Nintedanib in patients with progressive fibrosing interstitial lung disease (PF-ILD) (INBUILD).  Not currently recruiting

Back to top


California

Loma Linda University Scleroderma Center
Loma Linda University Faculty Medical Office

11370 Anderson Street, Suite 3650
Loma Linda, CA 92354
(909) 558-2860

Director: Vaneet K Sandhu, M.D., F.A.C.R., Rh.M.S.U.S.
Associate Director: Karina Torralba, M.D., F.A.C.R., M.A.C.M., Rh.M.S.U.S.

Physicians affiliated with this center:

Rheumatology:
Vaneet K Sandhu, M.D., F.A.C.R.
Karina Torralba, M.D. F.A.C.R., M.A.C.M., Rh.M.S.U.S.
Mehrnaz Hojjati, M.D., F.A.C.R.
Christina Downey, M.D., F.A.C.R.

Gastroenterology:
Yan Zhao, M.D., Ph.D.
Tejinder Kalra, M.D., F.A.C.G.
Terence Lewis, M.B.B.S., F.R.A.C.P., F.R.C.P.C., F.A.C.G., A.G.A.F.
Andrew Wright, M.D.

Pulmonary Hypertension:
Paresh Giri, M.D., F.C.C.P.

Interstitial Lung Disease:
Niranjan Jeganathan, M.D., M.S., F.C.C.P.

Cardiology:
Purvi Parwani, M.B.B.S., F.A.C.C.
Dmitry Abramov, M.D.
Evangelos Diamantakos, D.O., F.A.C.C.
Vinisha Garg, M.D., F.A.C.C.

Dermatology:
Betsy Furukawa, M.D., F.A.A.D.
Nancy Anderson, M.D., F.A.A.D.
Janiene Luke, M.D., MS, FAAD

Ongoing Studies:

Studies

Status

Southern California Scleroderma Registry (SCOSR)

Active, Recruiting

Southern California Interstitial Lung Disease Registry

Active, Recruiting

 

Scleroderma Center at Stanford UniversityStanford-Redwood City

Stanford University Scleroderma Center,
Stanford University Medical Center

Broadway St.
Department of Dermatology,
Pavilion B, 4th floor
Redwood City, CA  94063

Appointments: (650) 723-6961
Physician Inquiries: (650) 736-0727
Research Inquiries: (650) 725-4612

Director:  Lorinda Chung, M.D., M.S.
Associate Director: David Fiorentino, M.D., Ph.D.
Research Coordinators: Joel Nicholus and Marianna Stark

Physicians Affiliated with this Center:

  • Rheumatology:  Lorinda Chung, M.D., M.S., Jison Hong, M.D., Janice Lin, M.D., Robert Fairchild, M.D., Ph.D., Tamiko Katsumoto, M.D.
  • Gastroenterology: John Clarke, M.D., Linda Nguyen, M.D., Laren Becker, M.D., Nielsen Fernandez-Becker, M.D.
  • Pulmonary Medicine/Pulmonary Hypertension: Rishi Raj, M.D., Joshua Mooney, M.D., Tushar Desai, M.D., Roham Zamanian, M.D., Mark Nicolls, M.D.
  • Cardiology: Francois Haddad, M.D.
  • Dermatology: David Fiorentino, M.D., Ph.D., Matthew Lewis, M.D., Howard Chang, M.D., Ph.D.
  • Hand Surgery: James Chang, M.D.

Studies

Status

PHAROS: Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma

Active, not recruiting

Rituximab in SSc-APAH: A Randomized, Double-blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) in the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Active recruiting

A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis — A Double-Blind, Placebo-Controlled, Randomized Controlled Trial

Active, not recruiting

Outcomes and Clinical Biomarkers for Scleroderma

Active recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil for the Prevention of Calcinosis Progression

Active, recruiting

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of

GSK2330811 in Patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Active, not recruiting

Safety, tolerability and efficacy of JBT-101 in Diffuse Cutaneous Systemic Sclerosis

Active recruiting

SENSCIS: Safety and Efficacy of Nintedanib in Systemic SClerosIS Active recruiting

 

Scleroderma Center at San FranciscoSan Francisco

UCSF Scleroderma Center, University of California, San Francisco

400 Parnassus Avenue, Floor B-1
San Francisco, CA 94143

The UCSF Scleroderma Center evaluates and manages patients affected by the systemic and localized forms of scleroderma, Raynaud’s Phenomenon and other fibrosing skin disorders including eosinophilic fasciitis, scleromyxedema and scleroderma.

Contact Information for Clinical Appointments
Phone: 415-353-4403
Fax: 415-353-8463

Clinic Hours 
Wednesday, 8:00 AM - 4:00 PM

Thursday, 8:00 AM - 1:00 PM

Physicians Affiliated with this Center:

  • Pulmonary Medicine/Interstitial Lung Disease: Paul Wolters, M.D., Hal Collard, M.D.
  • Lung Transplant Program: Steven Hayes, M.D., Jeffrey Golden, M.D., Rupal Shah, M.D.
  • Cardiology/Pulmonary Hypertention: Teresa DeMarco, M.D., Van Selby, M.D., Munir Janmohamed, M.D.
  • Dermatology: M. Kari Connolly, M.D., Anna Haemel, M.D. 
  • Gastroenterology: Najwa El-Nachef, M.D.
  • Nephrology: Elaine Ku, M.D.
  • Hand Surgery: Lisa Lattanza, M.D. 

Research Coordinator

Brynn Kron

 

Studies

Status

UCSF Scleroderma Cohort

Active recruiting

Genome Research in African American Scleroderma Patients (GRASP) Study - NIH/NHGRI supported to discover and study  genes associated with increased risk for scleroderma and its manifestations in African American  patients Active recruiting
Eular Scleroderma Trials and Research (EUSTAR) Open
SENSCIS- Safety and Efficacy of Nintedanib in Systemic SClerosIS: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nintedanib versus Placebo in Patients with Scleroderma and Interstitial Lung Disease (SSc-ILD). Active recruiting

Resources

Los Angeles

University of California Los Angeles Scleroderma Center

UCLA Scleroderma Program

Director: Elizabeth Volkmann, M.D., M.S.

Clinic Address:
200 UCLA Medical Plaza, Suite 365
Los Angeles, CA 90095

Contact number for appointments: (310) 825-2448

Website for UCLA Rheumatology: https://www.uclahealth.org/rheumatology/

Website for UCLA CTD-ILD Program: https://www.uclahealth.org/ctd-ild/

Website for Research: https://www.uclahealth.org/rheumatology/Research

Rheumatologists:
Philip Clements, M.D., M.P.H.
Suzanne Kafaja, M.D.
Elizabeth Volkmann, M.D., M.S.

Pulmonologists:
John Belperio, M.D. (Interstitial lung disease, lung transplantation)
Richard Channick, M.D. (Pulmonary hypertension)
Ariss DerHovanessian, M.D. (Pulmonary hypertension, lung transplantation)
Joseph Lynch, M.D. (Interstitial lung disease, lung transplantation)
Allison Ramsey, M.D. (Interstitial lung disease, lung transplantation)
Michael Roth, M.D. (Interstitial lung disease)
Rajan Saggar, M.D. (Pulmonary hypertension, lung transplantation)
David Sayah, M.D. (Interstitial lung disease, lung transplantation)
Shelley Shapiro, M.D. (Pulmonary hypertension)
Mike Shino, M.D. (Lung transplantation)
Sam Weigt, M.D., M.S. (Interstitial lung disease, lung transplantation)

Radiologists:
Jonathan Goldin, M.D., Ph.D.
Lila Pourzand, M.D.
Rob Suh, M.D.

Cardiologists:
Eric Yang, M.D.

Gastroenterologists:
Jeffrey Conklin, M.D.
Terri Getzug, M.D.
Kevin Ghassemi, M.D.

 

Cedars-Sinai Scleroderma Center

Office practice location:
8723 Alden Drive, Suite 250
Los Angeles, CA 90048

Phone: (310) 423-6257
Fax (e-fax): (310) 423-6287

Physician Associated with this center: Francesco Boin, M.D., Director, Division of Rheumatology

 

Back to top


Colorado

University of Colorado Scleroderma Program

CO Anschutz

Aurora/Denver

University of Colorado Anschutz Medical Campus
Division of Rheumatology
Barbara Davis Center
1775 Aurora Court, P.O. Box 6511, Mail Stop B-115
Aurora, CO  80045

University of Colorado Rheumatology, http://www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/Rheumatology/Pages/Rheumatology.aspx

Physicians Afilliated with this Center:

Clinic Information: Hours: M–F 8 a.m. to 5 p.m.
Contacts: University of Colorado: (720) 848-7700 or (720) 848-4400

For anyone who may be interested in participating in any clinical studies, please contact Mallary Crow-Adams, (303) 724-8403 or mallary.crowadams@ucdenver.edu

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis 

Open

Scleroderma Lung Study III (SLS III): Combining the anti-fibrotic effects of Pirfenidone (PFD) with Mycophenolate (MMF) for treating scleroderma related interstitial lung disease

Open

Rituximab in SSc-APAH: A Randomized, Double-blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) in the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Open

 

National Jewish Health Logo PNGNational Jewish Health
Scleroderma Program
Main Campus
1400 Jackson St. Denver, CO 80206
njhealth.org/scleroderma

The Scleroderma Program at National Jewish Health offers patients comprehensive care and support. Our multidisciplinary scleroderma team includes specialists in rheumatology, interstitial lung disease, pulmonary hypertension, cardiology, gastroenterology and nephrology. We also offer the latest scleroderma clinical trials.

Appointments (patient self-referrals): (800) 621-0505

Physician Referrals: (800) 652-9555

Clinical Trials: njhealth.org/clinicaltrials

Physicians Affiliated with the Scleroderma Program:

Mehrnaz Maleki, M.D. - Rheumatology
Liudmila Kastsianok, M.D. - Rheumatology
Jeffrey Swigris, M.D. - Interstitial Lung Disease
M. Patricia George, M.D. - Pulmonary Hypertension
Arash Babaei, M.D. - Gastroenterology
Darlene Kim, M.D. - Cardiology

National Jewish Health Resources

Back to top


Connecticut

Farmington Connecticut Scleroderma CenterFarmington

UConn Health
Outpatient Pavilion

135 Dowling Way 
Farmington, CT  06030

Website: https://health.uconn.edu/msi/clinical-services/rheumatology/

Contact Information

 
 
Appointments: 
For more information or to make an appointment, call 860-679-2160 or 800-535-6232

 
Office Hours:
8 a.m. to 4:30 p.m. Monday through Friday

 
Rheumatologists associated with this center:
• Santhanam Lakshminarayanan, M.D.
• Ranadeep R. Mandhadi, M.D.
• William E. Traverse, M.D., FACR
 
 
The Rheumatology Center in the UConn Musculoskeletal Institute at UConn Health has nationally recognized experts in the diagnosis and treatment of connective tissue disorders like rheumatoid arthritis, lupus, scleroderma, Sjogren’s syndrome, and anti-phospholipid syndrome.

Research Information: Santhanam Lakshminarayanan, MD 860-679-3605

Studies

Status

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis

Closed

 

North Haven/New Haven

Yale Scleroderma Program

Yale Scleroderma Program

For referrals or to make an appointment:
Call Marie Frank
Phone: (203) 785-2454
Fax: (203) 785-7053
marie.frank@yale.edu

Rheumatology Clinic Location: Yale North Haven Medical Center
6 Devine St.
North Haven, CT  06473
Website: https://medicine.yale.edu/intmed/raci/rheumatology/programs/scleroderma/sclero/
Treats all forms of scleroderma, adults only

Physicians & Affiliated Health Care Providers

  • Rheumatology
    • Monique Hinchcliff, MD, MS (Director of Yale Scleroderma Program)
    • Victoria Esparo, APRN
  • Anesthesiology
    • Ruchi Sharma, MD
  • Cardiology
    • Lavanya Bellumkonda, MD
    • Margaret Furman, MD, MPH
    • Edward Miller, MD, PhD
  • Dermatology
    • Ian Odell, MD, PhD
    • Sarika Ramachandran, MD
    • Kathleen Suozzi, MD
  • Digestive Diseases
    • Amir Masoud, MD, MBBS
    • Mayra Sanchez, MD
  • Urogynecology
    • Hulda Einarsdottir, MD
  • Nephrology
    • Randy Luciano, MD, PhD
  • Pulmonary Medicine
    • Danielle Antin-Ozerkis, MD
    • Mridu Gulati, MD
    • Erica Herzog, MD, PhD
  • Pulmonary Vascular Medicine
    • Philip Joseph, MD
    • Inderjit Singh, MD, MCRP
  • Social Work
    • Deborah Smith, LCSW
  • Dietician
    • Laura Wilson, RD

Pulmonary Clinic Location: Yale Interstitial Lung Disease Center of Excellence
Scleroderma-Associated Lung Disease (ILD/Fibrosis &/or Pulmonary Hypertension)
Winchester Chest Clinic
Fitkin Memorial Pavilion
789 Howard Ave., 2nd Floor, New Haven, CT 06519
Appointment: (203) 785-4198
Fax: (203) 737-5453
Website: http://medicine.yale.edu/intmed/pulmonary

Clinical Studies

Status

Yale Rheumatology Bio-registry and Bio-repository
https://medicine.yale.edu/ycci/trial/7366/

Recruiting

Wnt-beta catenin target genes in macrophages and fibrosis
https://medicine.yale.edu/ycci/clinicaltrials/trial/6557/

Recruiting

KD025-209: A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
https://medicine.yale.edu/ycci/trial/6991/

Recruiting

KD025-215: A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Recruiting

Scleroderma Patient Centered Intervention Network (SPIN)

Recruiting

Rb-82 PET/CT Imaging in Patients with Systemic Sclerosis

Recruiting

If you would like to learn more about research or participate, please contact:
Yale Rheumatology Research
Alyssa Williams
scleroderma@yale.edu
(203) 737-5571

Research Website:
www.yale.edu/lab/hinchcliff/

Twitter: @YaleScleroderma

Back to top


District of Columbia

Georgetown University Scleroderma CenterWashington, D.C.

Georgetown University Hospital

Office Address:
Department of Rheumatology, Immunology & Allergy
3800 Reservoir Road, NW
3PHC, Suite 3004E
Washington, DC  20007

Clinical Address:
Georgetown University Hospital
PHC Building, Dept. of Rheumatology
3800 Reservoir Road, 6th Floor
Washington, DC  20007

Clinic Information: Adult and pediatric patients seen with localized and systemic scleroderma and other autoimmune conditions.

Physicians affiliated with this center:  Virginia Steen, M.D.

Clinic hours: Tuesday 9 a.m. to 3 p.m.; Tuesday 1 p.m. to 5 p.m.; Wednesday; some Fridays

Appointments: Ms. Walker (202) 444-6200

Physicians: (202) 444-6200, (202) 687-6316, or email steenv@georgetown.edu

Research Information: Sabrina Elliott, (202) 444-6210, se510@georgetown.edu; or Suzanne Bauguess, (202) 444-6211, smb228@georgetown.edu.

Name Description NCT
Number
GU Study
Coordinator
Scleroderma 
Patient 
Interaction 
Network (SPIN)
An online, survey-based study designed to discover where Scleroderma patients have access to a support network and serve as a way to learn more about Scleroderma patients.  N/A Sabrina Elliott
(202) 444-6210
se510@georgetown.edu
Genome Research
in African American 
Scleroderma Patients
(GRASP)
A genome-wide association study for African American Scleroderma Patients designed to identify novel genetic markers and inform future research and treatment for African American Scleroderma patients.  N/A Sabrina Elliott
(202) 444-6210
se510@georgetown.edu 
Prospective Registry of
Early Systemic Sclerosis (PRESS)
A prospective registry of early diffuse Scleroderma patients designed to collect clinical data and biological specimens to inform and support future research in order to understand the natural history of Scleroderma  N/A Sabrina Elliott
(202) 444-6210
se510@georgetown.edu
A Multicenter, Double-Blind,
Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud’s Phenomenon Secondary to Systemic Sclerosis (ES201)
This study is using a medication currently approved in Europe for Raynaud's Phenomenon secondary to Scleroderma, and the goal is to get approval for this potent medication in the United States.  This study will start recruiting patients in mid-March.   Sabrina Elliott
(202) 444-6210
se510@georgetown.edu
A Multicenter, Randomized,
Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis  (DETERMINE)
This study is planned to start in spring of 2019, it is looking at the impact of Lenabasum on improving dermatomyositis patients. This is a synthetic THC medication which has shown positive results in earlier trials.   Sabrina Elliott
(202) 444-6210
se510@georgetown.edu
Randomized, Multicenter,
Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of IgPro10 (intravenous
immunoglobulin, Privigen®) for the Treatment of Adults with Systemic Sclerosis (SSc) (IMPRESS)  
This study is looking to see the impact of an intravenous immunoglobulin, called Privigen, on improving the skin disease of patients with Systemic Sclerosis. It will be active in late 2019.   Sabrina Elliott
(202) 444-6210
se510@georgetown.edu
A Study of the Efficacy and
Safety of Bardoxolone Methyl
in Patients with Connective 
Tissue Disease-Associated 
Pulmonary Arterial Hypertension (CTD-PAH) (Catalyst)
Active, open to enrollment, This study assesses the safety and efficacy of Bardoxolone methyl relative to placebo in patients with connective tissue disease-associated pulmonary arterial hypertension to determine the recommended dose range and evaluate the change from baseline in 6-minute walk distance (6MWD) following 24 weeks of study participation. NCT02657356 Sabrina Elliott
(202) 444-6210
se510@georgetown.edu
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (RESOLVE) This study is assessing the efficacy and safety of Lenabasum for the treatment of diffuse cutaneous systemic sclerosis by improving the skin disease. This is a synthetic THC medication that has shown positive results in earlier phase trials. NCT03398837 Sabrina Elliott
(202) 444-6210
se510@georgetown.edu
Scleroderma Lung Study III: Combining the anti‐fibrotic effects of Pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma‐ related interstitial lung disease (SLS III) Starting early March, A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD). NCT03221257 Suzanne Bauguess
(202) 444-6211
smb228@georgetown.edu
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase I/II Multicenter, Randomized, Double Blinded, Safety Study (BRAVOS) This is an early phase study looking at test the impact of Brentuximab Vedotin on improving the skin disease of patients with Scleroderma. NCT03222492 Sabrina Elliott
(202) 444-6210
se510@georgetown.edu
An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension  (Ranger) This is a long-term access study made available to participants who were previously on Lariat and for participants completing the Catalyst trial to have access to the study medication prior to FDA approval. NCT03068130 Sabrina Elliott
(202) 444-6210
se510@georgetown.edu
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis (SENSCIS-ON Extension 1199.225) This is a long-term access study made available to participants who were previously on the BI SENSCIS 1199.214 trial to have access to the study medication prior to FDA approval.   NCT03313180 Sabrina Elliott
(202) 444-6210
se510@georgetown.edu
The COllaborative, National QUality and Efficacy Registry for Tracking Disease Progression in a Spectrum of Systemic Sclerosis (Scleroderma) Patients (CONQUER) A prospective registry of Scleroderma patients designed to collect clinical data and biological specimens to inform and support future research in order to understand the natural history of Scleroderma as an extension of Standard of Care practices  NA Sabrina Elliott
(202) 444-6210
se510@georgetown.edu

Back to top


Illinois

Northwestern University Scleroderma CenterChicago

Northwestern Scleroderma Program, Northwestern Medicine
675 N St Clair St, Suite 14-100, Chicago, IL  60611 (Clinical Offices)
240 E Huron St, M-300, Chicago, IL  60611 (Research Laboratories)
http://www.scleroderma.northwestern.edu/ (website)

Appointments: (312) 695-8628 (Returning patients)
Physician Inquiries & New Patient Appointments: (312) 695-6119
Research Inquiries: (312) 503-1137
Fax: (312) 695-6060

Mary Carns, M.S., Research Coordinator
Chase Correia, M.D.
Elisa Hoellerich, P.A.-C.

Physicians Affiliated with this Center:

PA-C

  • Gastroenterology: Ikuo Hirano, M.D., Darren Brenner, M.D.
  • Nutrition: Bethan Doerfler, M.D.
  • Pulmonary Medicine/Pulmonary Hypertension: Jane E. Dematte, M.D., Michael Cuttica, M.D., M.S., and Stuart Rich, M.D.
  • Cardiology: Sanjiv Shah, M.D. and Benjamin Freed, M.D.
  • Dermatology/Dermatopathology: Anne Laumann, M.B.Ch.B., M.R.C.P. (U.K.), and Emily Keimig, M.D.
  • Hand Surgery: Robert Galiano, M.D.
  • Nephrology: Cybele Ghossein, M.D.
  • Lung Transplant: Sangeeta Bhorade, M.D.
  • Immunotherapy: Richard Burt, M.D.
  • Photopheresis: Jaehyuk Choi, M.D., Ph.D.
  • Hematology and Oncology: Jayesh Mehta, M.D.
  • Neuromuscular: Jinny Tavee, M.D.
Studies Status
Mechanisms of Fibrosis in Scleroderma Active
Genetic Polymorphisms in Scleroderma Active
Novel Biological Therapies for Scleroderma Lung Disease Active
Scleroderma Biomarker Studies Active
Northwestern Scleroderma Program Patient Registry Active

 

University of Chicago Scleroderma CenterUniversity of Chicago, Scleroderma Clinic
5841 South Maryland Ave., Chicago, IL 60637

Clinic Information: Adult patients seen with systemic and localized scleroderma. Hours: 8 a.m. to 5 p.m Monday through Friday.

Physicians Affiliated with this Center:

  • Michael Becker, M.D.
  • Marcus Clark, M.D.
  • James Curran, M.D.
  • Reem Jan, M.D.
  • Kim Trotter, M.D.
  • Kichul Ko, M.D.
  • Vladimir Liarski, M.D..

Appointments: (773) 702-6119 or 1-888-824-0200
Research Information: Marcus Clark, MD at mclark@medicine.bsd.uchicago.edu

 

University of Illinois at ChicagoClinic Information: AKC Clinic
University of Illinois at Chicago Outpatient Care Center (OCC)

1801 West Taylor St., Suite 3A, 3rd Floor, Chicago, Illinois 60612

Patients Seen: Adults, systemic and localized sclerosis; Hours: 8 a.m. to 5 p.m. Monday- Friday

  • Shiva Arami, M.D.
  • Anjali Mehta, M.D.
  • Suncica Volkov, M.D.

Appointment Scheduling: (312) 413-5569
Physician Inquiries: (312) 355-5079
Clinic information: Bernie Mac Sarcoidosis Translational Advanced Research (STAR) Center University of Illinois at Chicago Outpatient Care Center (OCC)
1801 West Taylor St., Suite 3C, 3rd Floor, Chicago, Illinois 60612

Patients Seen: Sarcoidosis
Physician Affiliated with this Center:

  • Nadera Sweiss, M.D.

Appointment Scheduling: (312) 996-5723

Research Contact: Hasib Zabih, hzabih2@uic.edu

 

University of Illinois at Chicago, Section of Rheumatology
1819 W. Polk St., A312 M/C 733, Chicago, IL 60612

Appointments: (312) 413-4244
Physician Affiliated with this Center: Nadera J Sweiss, M.D.
Research Coordinator- Latriese V Sardin- (312) 413- 9310

Study of Pomalidomide (CC-4047) to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects with Systemic Sclerosis with Interstitial Lung Disease: www.sclerodermastudy.com

Actively Recruiting

Back to top


Louisiana

New Orleans

Tulane University School of Medicine - Tulane Lung Center

1430 Tulane Ave, 7th floor
Phone: (504) 237-5720
 
Southeast Louisiana Veterans Health Care System
1601 Perdido Street, New Orleans, LA  70112
Phone: (504) 237-5720
(Ask any of your VA doctors to request consult with Dr. Saketkoo.)

University Medical Center Comprehensive Pulmonary Hypertension Center
3000 Canal St; New Orleans, LA 70112
Phone: (504) 237-5720

Hospitals Served: Tulane University Medical Center, VA Hospital, University Medical Center (public hospital, a.k.a. University Hospital, Charity Hospital, and MCLNO)

  • Lesley Ann Saketkoo, M.D., M.P.H. – Director; Associate Professor of Medicine at Tulane University School of Medicine; Sections of Immunology and Pulmonary Medicine
  • Monique Brown, R.N. Nurse Coordinator for University Medical Center CPHC 
  • Mona Crum, R.N. Nurse Coordinator for Tulane Lung Center
  • Sandy Ditta, R.N. Senior Research Coordinator
  • Christine Glynn, R.N. Research Coordinator 
  • Vjayendra Jaligam, M.D. - Cardiology
  • Raman Danrad, M.D. - Radiology
  • Bennett de Boisblanc, M.D. - Pulmonary Medicine / Pulmonary Hypertension
  • Matthew Lammi, M.D. - Pulmonary Medicine / Pulmonary Hypertension
  • Monika Kowalczyk, M.D. - Gastroenterology
  • Tamarin Hennebury, L.O.T.R. - Director of Therapeutic Wellness (Physical and Occupational Therapy)
  • Erin Boh, M.D. – Dermatology

Studies

Status

Eular Scleroderma Trials and Research (EUSTAR)

Open

Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS)

Closed for new recruitment

Incidence, Prevalence of Systemic Sclerosis in the Louisiana and Gulf Area Study

Open

Patient Perspectives in Systemic Sclerosis Interstitial Lung Disease

Open

Patient Perspectives in Systemic Sclerosis Pulmonary Hypertension

Open

Patient Perspectives in Calcinosis

Open

Development of World Health Organization's International Classification of Functioning, Disability and Health Core Set in Systemic Sclerosis

Open

GRASP - Genome Research in African American Scleroderma Patients (GRASP) Study - which is an NIH funded study examining clinical features and genetics of scleroderma in a population that experiences severe manifestations of scleroderma.

Open

Endothelial Micro-particles in Systemic Sclerosis

Open

Sexual Dysfunction in Pulmonary Hypertension

Open

Multidimensional Fatigue In Pulmonary Hypertension

Open

Several current clinical trials in Pulmonary Hypertension

Open

Randomised Placebo Controlled Trial of Diet Impact in Systemic Sclerosis  Open
Developing a Patient Reported Outcome Measure in Systemic Sclerosis related Calcinosis Open
Development of a Patient Reported Raynaud Outcome Measure (African American Branch of Study)  Open
Development of an International Educational Capillaroscopy Image Bank Open
Randomized Placebo Controlled Clinical Trial in Lenabasum Open for Enrollment February 2018

Monthly support group meets at Tulane, please contact Support Group Leaders, Ms. Paige St Pierre, kpmec@viscom.net (985) 696 5409 and Ms. Joy Mitchell, (504) 301-7737 joymitchell78@gmail.com or Ms. Paige St. Pierre, Support Group Co-Leader (985) 696-5409   paige.stpierre@yahoo.com.

Back to top


Maryland

Johns Hopkins Scleroderma CenterBaltimore

Johns Hopkins University School of Medicine, Johns Hopkins Scleroderma Center
5501 Hopkins Bayview Circle, Baltimore, MD  21224

Website: www.hopkinsscleroderma.org

Clinic Information:  Sees patients with systemic and localized forms of scleroderma, Raynaud’s, scleromyxedema, eosinophilic fasciitis, and scleroderma.
Hours: 9 a.m. to 3:30 p.m., Monday through Friday.

Physicians Affiliated with this Center:

  • Fredrick Wigley, M.D., Director
  • Laura Hummers, M.D., Sc.M., Co-Director
  • Ami Shah, M.D., M.H.S.
  • Zsuzsanna McMahan, M.D., M.H.S.
  • Julie Paik, M.D., M.H.S.
  • Nadia Morgan, M.D., M.H.S.
  • Christopher Mecoli, M.D., M.H.S.

Clinical Appointments:  Medical office coordinators at (410) 550-7715; Fax (410) 550-1363; New patient requests/records faxed to (443) 267-0090; scheduling office (443) 997-1552.

Research Information: Gwen Leatherman, Clinical Research Nurse Coordinator: (410) 550-8582, gleathe@jhmi.edu

Research Interests: Raynaud’s Phenomenon, Scleroderma Lung Disease, Autoimmunity and Cancer, and Vascular Disease, Hypopigmentation

Studies

 

Status

Clinical Epidemiology of Lung Disease and Other Features of Scleroderma and Other Connective Tissue Diseases

Longitudinal study designed to help understand the cause of lung disease and other clinical features of scleroderma and other connective tissue diseases.

Call for status/more information

Do Cancer Antigens Propagate an Immune Response and Activate the Disease Process in Scleroderma?

Study aimed at investigating the link between cancer and scleroderma.

Call for status/more information

Genome Research in African American Scleroderma Patients (GRASP)

Study focusing on genetic markers within African American scleroderma patients in order to better understand the need for future research and treatments.

Call for status/more information

Johns Hopkins Scleroderma Center Cutaneous Tissue Repository (Patients and Controls)

Skin biopsy samples from patients and controls used to establish a skin tissue bank to further investigate the development of scleroderma and scleroderma-like diseases.

Actively recruiting

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis or SSc-associated Pulmonary Arterial Hypertension

This study is a randomized, placebo-controlled; double-blind phase 2 trial of patients with dcSSc or SSc-PAH. Twenty participants with SSc-PAH and 14 participants with dcSSc will be randomized to receive either oral ifetroban daily or matching placebo. Study participants will be treated for 12 months, followed by a 30-day follow-up period. The study will test whether Ifetroban is safe and statistically superior to placebo in reducing the effects of their disease at month 12 and explore the ability of Ifetroban to prevent or reverse progression in patients with early disease duration and reverse established disease in patients with longer disease duration.

Actively recruiting

Proof of Mechanism Study of GSK2330811 in Diffuse Systemic Sclerosis

This multi-center, randomized, double-blind (sponsor open), placebo controlled, proof of mechanism study will be the first study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of repeat subcutaneous (SC) doses of GSK2330811 in male and female participants with diffuse cutaneous SSc (dcSSc). Participants with active disease and a disease duration of <= 60 months will be enrolled.

Actively recruiting

Scleroderma and Gastrointestinal Disease: Insights into Clinical Phenotypes and Disease Pathogenesis

Patients with and without scleroderma GI disease.  Aim is to improve the approach to diagnosis and management of gastrointestinal disease in scleroderma through investigation of WGT (whole gut transit study).

Call for status/more information

Scleroderma Patient Intervention Network (SPIN)

Participants will be asked to complete online questionnaires every 3 months.  The long-term goal of the study is to develop a way to offer low cost, easily accessible interventions that will improve quality of life.

Actively recruiting

Studies of Serum Plasma Factors in Systemic Sclerosis, Raynaud’s Phenomenon, and Other Connective Tissue Diseases

Longitudinal collection of blood specimens to better understand the cause and activity level of systemic sclerosis, Raynaud’s phenomenon, and other connective tissue diseases.

Call for status/more information

Studies of Serum Plasma Factors in Systemic Sclerosis, Raynaud’s Phenomenon, and Other Connective Tissue Diseases (Control)

Longitudinal collection of blood specimens from healthy controls.

Call for status/more information

The Study of Discordant Twins in Scleroderma

Collection of blood sample and medical history from twin with scleroderma as well as from the twin without scleroderma

Call for status/more information

Scleroderma Lung Study III: Combining the anti-fibrotic effects of pirfenidone with mycophenolate for treating scleroderma-related Interstitial Lung Disease

Clinical trial for individuals with new onset lung disease

Call for status/more information

Collaborative National Quality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (Scleroderma) Patients (ConQuer)

Registry to develop a large observational group of early Scleroderma patients that will foster research collaboration, expanded geographical reach as well as establish an infrastructure for future Scleroderma studies.

Actively Recruiting

Back to top


Massachusetts

Boston University Scleroderma CenterBoston

Boston University Scleroderma Program
Shapiro Ambulatory Care Center
725 Albany Street, 7th Floor, Suite 7B (Clinical Offices)
Boston, MA 02118

Scleroderma Center
72 East Concord Street, Evans 501 (Research Offices)
Boston, MA 02118

https://www.bumc.bu.edu/rheumatology/scleroderma/

Patient Appointments: Tracy Keane (617) 358-3829, trkeane@bu.edu
For trial-related inquiries: Kimberly Finch (617) 358-3839, kimtobin@bu.edu

Scleroderma Specialists Affiliated with this Center

Rheumatology:
Michael York, M.D.
Maarcin Trojanowski, M.D.
Andreea Bujor M.D., Ph.D.

Pulmonary Medicine/Pulmonary Hypertension/Interstitial Lung Disease:
Harrison Farber, M.D.
Arthur Theodore, M.D.

Dermatology/Dermatopathology:
Christina Lam, M.D.

Study Name

Objective

Enrollment Status

Phase II Randomized, Placebo-controlled, double-blind study to evaluate the efficacy and safety of KD025 in Diffuse SSc

(KD025-209) 

Evaluate efficacy of KD025

Enrolling

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care

(ROR-PH-301)

Evaluate efficacy of ralinepag in pulmonary arterial hypertension patients (PAH)

Enrolling. Those complete can continue to extension study

Randomized, Double Blind Placebo Controlled, Repeat Dose to Evaluate HZN-825 in Patients with Diffuse SSc (Horizon)

Evaluate efficacy of HZN-825 for treatment of diffucse cutaneous SSc

Enrolling Summer/Fall 2021

Repository for Scleroderma and Control Skin and Blood Samples

Rather than discard, excess skin and blood samples and data will be stored for research. PIs can request repository samples for scleroderma research.

Enrolling

 

Scleroderma Center of Research Translation – Biomarkers

(CORT/SCaR)

Collecting skin biopsies and blood from SSc patients and controls to identify biomarkers of progressive skin disease.

Enrolling

 

 



Scleroderma Program - Massachusetts General Hospital

MGH Boston
55 Fruit St, Yawkey 2C-2100
Boston, MA 02114

MGH Waltham
52 Second Ave., Suite 2600
Waltham, MA 02451

Website: http://massgeneral.link/scleroderma

Clinic Information: We see adult patients with morphea (localized scleroderma), systemic sclerosis and associated fibrosing conditions

Telephone Hours: 9 am - 4 pm Monday-Friday

Clinic Appointments by Referral Only: (T) 617-726-7938 (F) 617-643-1274

Physicians Affiliated with this Center:

  • Flavia Castelino, M.D, Program Director
  • Marcy Bolster, M.D.
  • Sara Schoenfeld, M.D.

Research Inquiries: 617-726-2792, Fax: 617-643-1274
ADFERNANDES@mgh.harvard.edu, (Ana Fernandes, Research Manager)

Studies Status
PRISM (Prospective Registry/Repository in Scleroderma at MGH) - Database and biorepository of patients with scleroderma at the MGH Scleroderma Program Active, recruiting
Lysophosphatidic Acid (LPA) as a Biomarker in Scleroderma- evaluate whether LPA levels in the blood and skin can help us understand disease progression in scleroderma Active, recruiting
Ifetriban in Diffuse Systemic Sclerosis or Systemic Sclerosis-Associated Pulomary Hypertension (Phase II Trial) Active, recruiting
Prospective Registry in Early Systemic Sclerosis (PRESS) - A collaborative, multi-center database of patients in the early stages of scleroderma. Active, recruiting
Scleroderma Clinical Trials Consortium (SCTC) Calcinosis Working Group - A collaborative, multi-center database of patients with scleroderma and calcinosis. Active, recruiting
Lenabasum in Diffuse Cutaneous Systemic sclerosis (Phase III Trial) Active, recruiting
The Collaborative, National Quality, and Efficacy Registry (CONQUER) - A collaborative, multi-center database of patients with scleroderma Active, recruiting
GLPG1690 (Autotaxin inhibitor) for 24 weeks in subjects with systemic sclerosis (Phase II Trial) Upcoming

Back to top


MichiganUniversity of Michigan Division of Rheumatology

University of Michigan Scleroderma CenterAnn Arbor

University of Michigan, Scleroderma Program
3rd Level Taubman Center
Clinic Areas A
Ann Arbor, MI  48109-0370

Appointments: (734) 647-5900 or (888) 229-3065
Physician Inquiries: (734) 647-5900

Scleroderma Program Website: http://www.med.umich.edu/scleroderma/

Scleroderma Research Manager: Erica Bush (734) 936-5615, ebush@med.umich.edu

Research Inquiries: ssc-coordinator@umich.edu

  • Dinesh Khanna, M.D., M.S. Director
  • Amber Young, M.D.
  • Vivek Nagaraja, M.D.

General questions:  ssc_coordinator@umich.edu
For physicians: khannad@med.umich.edu

STUDY

DESCRIPTION

CONTACT/PI

GSK2330811

A multi-centre, randomized, double-blind (sponsor open), placebo-controlled, repeat-dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and explore efficacy of GSK2330811 in participants with diffuse cutaneous systemic sclerosis.

  • 12 week Double Blind/ 16 week follow up
  • 20-40 subjects across two cohorts
    • Some background therapies including mycophenolate (3 grams/stable dose last 3 months) and low dose oral corticosteroids (<10 mg stable 1 month) are allowed.
  • Bi- weekly 100/300 mg of GSK2330811 or placebo sub cutaneous injections. Totaling 6 injections of the course of the study.
  • Disease duration: <60 and mRSS >10 and < than 35 at screening plus additional active disease criteria: increasing skin involvement in the last 6 months, disease duration of <18 months or CRP of >6 mg/l) 
  • FVC <50% of predicted or DLCO corrected <40% of predicted are exclusionary.  
  • Optional blister biopsy 



Recruiting April 2018

Monica Sanborn

734-232-2090
jaafarsa@umich.edu
PI: Dr. Nagaraja

GLPG1690

A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis

  • 24-week Double Blind/ 16 week follow up/li>
  • 30 subjects
  • Daily dosage of 600mg study drug/placebo with a 2:1 ratio. Disease duration: <60months and mRSS >10
  • FVC < 45% of predicted within last 6 months is exclusionary
  • Prohibited medications within 3 months prior to the baseline visit and during the treatment period: prednisone or its equivalent >10 mg/day, methotrexate>20 mg/week, azathioprine >150 mg/day, MMF >3 g/day, mycophenolic acid >2.16 g/day, and leflunamide >20 mg/day
  • Clinically significant abnormalities detected on ECG at screening of either rhythm or conduction, QTcF >450 ms, or a known long QT syndrome.
  • Biopsies required at two time points


Recruiting

Sara Jaafar

734-232-2119
monsan@med.umich.edu 

PI: Dr. Khanna

BRAVOS

Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase ½ Multicenter Randomized, Double Blinded, Safety Study

  • Three ascending dose cohorts will receive brentuximab/placebo (0.6mg/kg, 1.2mg/kg and 1.8mg/kg. Each cohort will receive intravenous administration every 3 weeks for 21 weeks, with a total of 8 doses. 24 participants with 8 in each cohort.
  • Double blind treatment for 21 weeks followed by 27 weeks of follow up.
  •  Disease duration: <60 and mRSS > 10 and <45 at screening plus additional active disease criteria: increasing skin involvement in the last 6 months or an mRSS that has not decreased >3 units within last 6 months or meets protocol specific criteria around SSc lung disease.  
  • Documentation of at least 12 weeks of ongoing immunosuppressive therapy for SSc at time of enrollment with 4 weeks of stable dose for: methotrexate <25mg, mycophenolate <3g, or Azathioprine <3mg/kg/day.
  • FVC <60% of predicted or DLCO corrected <60% of predicted are exclusionary
  • Skin biopsies at two time points.

Recruiting
Monica Sanborn

734-232-2090
monsan@med.umich.edu 

PI: Dr. Khanna

RAYNAUDS PHENOMENON 

 

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects with Symptomatic Raynaud’s Phenomenon Secondary to Systemic Sclerosis

  • 5-day outpatient infusion of iloprost versus placebo with 1:1 randomization
  • 40 subjects
  • Diagnosis of SSc and Raynaud’s Phenomenon with at least a 2-phase color change in fingers
  • History of lung disease as defined by FVC of <45% predicted is exclusionary.
  • Stable dose of vasodilators including PDE5 inhibitors such as sildenafil, is required 2 weeks prior to screening.
  • Epoprostenol requires a wash-out of 8 weeks prior to screening.
  • 10 symptomatic RP attacks, documented in the ePRO diary, occurring over at least 3 separate days of the 5-day eligibility period



Recruiting
Sara Jaafar

734-936-5615
jaafarsa@umich.edu

PI: Dr. Nagaraja

LUNG FIBROSIS 

SLS 3

Combining the anti‐fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma‐ related interstitial lung disease.

  • 18- month double blind, phase 2 with 1 month follow up visit
  • 150 subjects
  • Mycophenolate 250mg capsules + Pirfenidone 267mg capsules or placebo.  The dosage will escalate if tolerated over a monthly 4 step titration plan.
  • FVC‐% of <80% at screening and Grade >2 on the Magnitude of Task component of the Mahler Modified Dyspnea Index are inclusionary. 
  • FVS-% of 45% at screening or baseline; FEV1/FVC ration <0.68 at screening or baseline and DLCO corrected -% of 30% are all exclusionary.  
  • Disease duration of <84 months
  • Extensive prohibited medication list with wash-out of at least 30 days, refer to protocol.



Recruiting:
Monica Sanborn

734-232-2090
monsan@med.umich.edu

Dr. Nagaraja

JOINT CONTRACTURES 

REACH

Novel Rehabilitation Strategies to improve are function in patients with Scleroderma 

  • Have a diagnosis of systemic sclerosis, diffuse cutaneous subset; disease duration < 5 years from 1st non Raynaud phenomenon sign or symptom
  • Have a contracture of the hand and other joint in at least one arm, such as wrist, elbow, or shoulder, with the ability to demonstrate active range of motion in that arm
    • Willing to travel to participate in therapy and outcome assessments.
    • Have an Android, iPhone, iPad or computer tablet to load the home exercise App



Recruiting
Maya Sabbagh

734-232-2090
msab@med.umich.edu

Dr. Khanna/Dr. Murphy

Back to top



Minnesota

Minneapolis

MHealth
Rheumatology Clinic
Clinics and Surgery Center

909 Fulton St. SE, Minneapolis, MN  55455
Information: (612) 626-6100; Fax: (612) 676-5048
Appointments: (612) 626-6100, option 2

Maple Grove

Rheumatology
University of Minnesota Health Maple Grove Clinics

Floor 2, Desk 4, 14500 99th Ave. N, Maple Grove, MN  55369

Information & Appointments: (763) 898-1080

Physicians associated with the facility:

● Gastroenterology: Dr. Jose Vega-Peralta, Dr. Alexander Khoruts, Dr. Mustafa Arain, Savanna Borne, M.S.N.

● Pulmonary: Dr. Hyun Kim, Dr. David Perlman, Dr. Rade Tomic, Dr. Craig Henke, Dr. Peter Bitterman

● Cardiology: Dr. Mark Pritzker, Dr. Thenappan Thenappan, Dr. Rebecca Cogswell

● Rheumatology: Dr. Jerry Molitor

R.N. Care Coordinator: Lee Anderson; she can be reached at the clinic phone number.

Studies

Status

ASCO-1: "A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituzimab) for the Treatment of Systemic Sclerosis". The primary study objective is to compare patients with SSc-PAH treated with rituximab to those on placebo for change in exercise capacity, as determined by the 6MWT. The secondary objectives are to compare treatment groups for other measures of disease progression and to determine whether the effects on clinical disease progression are paralleled by changes in selected biomarkers. Safety and tolerability of rituximab for the treatment of SSc-PAH in patients currently

ACTIVELY ENROLLING

 

Rochester 

Mayo Clinic (Rochester)
200 1st St SW, Rochester, MN  55905

Clinic contact: Appointments are by Referral Only
Division of Rheumatology Appointment Office: Ph: 507-284-4550, Fax: 507-284-5508
Or Central Appointment Office: Ph: 507-266-5800, Fax:  800-321-1368

Clinic hours: Mon-Fri 8 am to 5 pm (variable depending on the physician staff)
Current Studies Status
1. Incidence, Prevalence and Mortality of Scleroderma in Olmsted County Active
2. Cardiovascular risk factors and Cardiac events in Scleroderma
Active
3. Incidence, Prevalence and Outcomes of Eosinophilic fasciitis in Olmsted County Active
 
Clinical Trials Status
1. SENSCIS- Safety and Efficacy of Nintedanib in Systemic Sclerosis: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nintedanib versus Placebo in Patients with Scleroderma and Interstitial Lung Disease (SSc-ILD)
Active, Not Recruiting
2. A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis — A Double-Blind, Placebo-Controlled, Randomized Controlled Trial
Inactive, Not recruiting
3. An observational multicenter international case-control study for the assessment of nailfold capillary abnormalities in patients with systemic lupus erythematosus
Active, Not recruiting

Physicians Affiliated:

Rheumatology, Connective Tissue Disease Group
:
Dr. Ashima Makol, Dr. Thomas Osborn, Dr. Shreyasee Amin, Dr. Thomas Mason, Dr. Kevin Moder, Dr. Floranne Ernste, Dr. Uma Thanarajasingam

Dermatology:
Dr. David Wetter, Dr. Lisa Drage, Dr. Mark Davis, Dr. Alina Bridges, Dr. Michael Camilleri, Dr. Rokea el-Azhary, Dr. Lawrence Gibson, Dr. Marian McEvoy, Dr. Margot Peters, Dr. Gabriel Sciallis

Pulmonology ILD Clinic:
Dr. Jay Ryu, Dr. Teng Moua, Dr. Misbah Baqir, Dr. Sanjay Kalra

Pulmonary Hypertension Clinic:
Dr. Robert Frantz, Dr. Garvan Kane, Dr. Michael J. Krowka, Dr. Sudhir S. Kushwaha, Dr. Robert B. McCully, Dr. Michael D. McGoon, Dr. Joseph G. Murphy

Pediatric patients are also seen

Pediatric Rheumatology
:
Dr. Thomas Mason

Pediatric Dermatology
:
Dr. Dawn Davis, Dr. Megha Tollefson

Most patients are initially evaluated in rheumatology or dermatology and referred to other areas.  Depending on the need, we have experts in many areas including but not limited to nephrology, GI motility, vascular medicine, wound care, orthopedics, physical medicine and occupational therapy.  We offer nailfold videocapillaroscopy, vascular studies, high resolution chest CT and echocardiography specific for pulmonary hypertension evaluation. We have nurses and education clinics, where patients are educated about their disease, medications, and provided other resources for optimal management of scleroderma. 

Back to top


New Hampshire

Lebanon

Dartmouth Hitchcock Medical Center
1 Medical Center Dr.
Lebanon NH 03756

Phone: 603-650-8622
Fax: 603-650-4961

Clinic hours are 8 a.m. - 5 p.m.
Appointments are by referral only
Treats adults and children and all forms of the disease, localized and systemic sclerosis.

Website: http://med.dartmouth-hitchcock.org/rheumatology.html

Physicians affiliated with this center:
Rheumatology: Nicole Orzechowski, D.O. and Daniel Albert, M.D.
Pulmonology: Alex Gifford, M.D. and Richard Enelow, M.D.
Dermatology: Dorothea Barton, M.D.
Cardiology: Bruce Andrus, M.D.
Vascular Surgery: Michael Matthew, M.D.
Basic Science: Michael L. Whitfield, Ph.D. and Patricia A. Pioli, Ph.D.

Studies Status
Molecular Characterization of Multi-Organ Involvement in Patients with Systemic Sclerosis Active
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis Call for details

Back to top


New Jersey

Hackensack

Division of Pediatric Rheumatology, Joseph M. Sanzari Children’s Hospital
Hackensack University Medical Center
Hackensack Meridian School of Medicine at Seton Hall University
Pediatric Rheumatology Clinic
30 Prospect Ave., Hackensack, NJ  07601

https://www.hackensackumc.org/services/pediatrics/pediatric-services/pediatric-rheumatology-arthritis/

Phone: 551-996-5306 (appointments and information - by referral only)
Fax: 201-996-9815

Clinic Information:
Patients who have localized scleroderma/morphea, systemic sclerosis, stiff skin syndrome, or other sclerosing diseases are seen by referral. Practice is limited to patients from newborn to 22 years of age.

Appointments are held in the Pediatric Rheumatology offices
on the 3rd floor of the WFAN-Imus Pediatric Building. 
Hours: Monday-Friday: 830 a.m. - 5 p.m.

Physicians affiliated with this center:

Rheumatology:

  • Suzanne C. Li, M.D., Ph.D.
  • Yukiko Kimura, M.D.
  • A. Carmelo Gironella, M.D.
  • Ginger Janow, M.D.
  • Sivia Lapidus, M.D.
  • Jennifer Weiss, M.D.

Dermatology:

  • Helen Shin, M.D.
  • Emily Berger, M.D.
  • Julie Schaffer, M.D.

Radiology:

  • Melissa Liebling, M.D.
  • Mike McGuire, M.D.

Clinic contact: Johnslyn Rochester

Studies Status
Identifying Juvenile Scleroderma (Localized and Systemic) Immunophenotype Subsets Actively Recruiting
Development of Clinical Disease Outcome Measures with Biological Substudies for Localized Scleroderma (LOCUS-2) Actively Recruiting
Evaluation of Ultrasound Imaging for Localized Scleroderma monitoring Actively Recruiting
A Prospective Observational Study Comparing the Non-inferiority of Mycophenolate Mofetil to Methotrexate for the Treatment of Juvenile Localized Scleroderma Recruitment to begin in 2019
Juvenile Localized Scleroderma Consensus Treatment Plan pilot study Closed to enrollment, in data analysis

 

New Brunswick Scleroderma Center

New Brunswick

Rutgers-RWJ Scleroderma Program
125 Patterson Street, CAB, 5th floor
New Brunswick, NJ  08903
Office: (732) 235-7217; Fax: (732) 235-6526

Office hours: Mon 8-12,  Tues 8AM-4PM and Wed 8AM-4PM

Adult Clinical Research Center 
125 Paterson Street, 
East Tower, 8th floor
New Brunswick, NJ  08903
Main number:  (732) 235-6402

Clinic Information: Adult patients seen with Morphea, Localized and Scleroderma Spectrum disorders. 

Hours:
New patients seen on Tuesdays from 8 a.m. to 12 noon.
Follow-up patients seen on Wednesdays 8 a.m. to 5 p.m.

Appointments and information: (732) 235-7217; Fax: (732) 235-6526

Physician inquiries: (732) 418-8484 (Clinical Research Center)

Physicians Affiliated with this Center:
Vivien M. Hsu, M.D., Professor of Medicine, Director, Rutgers- RWJ Scleroderma Program Program Director, Rutgers-RWJ Rheumatology Fellowship Program

 

Studies

Status

 

NIH/Scleroderma Research Foundation
Genome Research in African-American Scleroderma patients (GRASP)

 

 

opened since 2015, recruiting

 

Corbus Pharmaceuticals
Open-Label Multicenter study to evaluate safety, tolerability, efficacy and pharmacokinetics of Anabasum in systemic sclerosis.

opened since 2017

Merck
A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)

CLOSED

Corbus Pharmaceuticals:
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Efficacy and Safety of Anabasum in Diffuse Cutaneous Systemic Sclerosis (RESOLVE)

actively enrolling

Genentech, UCLA: 
Scleroderma Lung Study III (SLS III): Combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related interstitial lung disease.
actively enrolling
IV Iloprost for Scleroderma Raynaud (EICOS/MEDPACE opening soon

 

Back to top



New York

 

Great Neck

Northwell Health Division of Rheumatology

Primary Location:
865 Northern Blvd, Suite 302, Great Neck, NY  11021

Satellite Locations:
95-25 Queens Boulevard, Rego Park, NY  11374
180 East Main Street, Suite A. Bayshore, NY  11706
241 East Main Street, Suite 2C. Huntington, NY  11743

Research Information Contact: Rheumatology Research at (516) 708-2546 or RheumResearch@Northwell.edu

General information: Adult patients seen with systemic and localized scleroderma
Questions/appointments: (516) 708-2550

Physicians Affiliated with this Center:
Primary Physician Contact: Sonali Narain, M.D.

  • Richard Furie, M.D.
  • Galina Marder, M.D.
  • Maria Louise Barilla-LaBarca, M.D.
  • Diane Horowitz, M.D.
  • Julie Schwartzman-Morris, M.D.
  • Elena Katzap, D.O.
  • Kamini Shah, M.D.
  • Myron Kleiner, M.D.
  • Michael Repice, M.D.
  • Joseph Mosak, M.D.
  • Yaqoot Khan, M.D.
  • Christine Stamatos, D.N.P.
  • Monica Richey, N.P.
Studies Status
Medimmune Sample Acquisition Study: Patients with Diffuse Cutaneous Scleroderma Recruiting
BMS Sample Acquisition Study: Patients with Skin Tightening Recruiting
STRATUS Clinical Trial: abituzumab for patients with systemic sclerosis and associated ILD Study Terminated
ASSET Clinical Trial: abatacept for patients with recent diagnosis of diffuse cutaneous systemic sclerosis Completed Recruitment

 

Ballston Spa

Steffens Scleroderma Center
Albany Med Malta Multispecialty
6 Medical Park Drive, Suite 203, MC-200
Ballston Spa, NY 12020

Physicians at this center:

  • Lee Shapiro, M.D.

To schedule an appointment: (518) 262-5345

 

New York City
hospital special surgery scleroderma
HSS, Scleroderma, Vasculitis, & Myositis Center
The Department of Medicine/Division of Rheumatology
The Hospital for Special Surgery
535 East 70th Street
NY, NY,  10021
(212) 774-2048; (212) 774-2358 fax
Website: http://www.hss.edu/scleroderma-vasculitis-center.asp

Clinic Information:  Adult patients seen with systemic and localized scleroderma.
Hours: 9 a.m. to 5 p.m. Monday through Friday.

Physicians Affiliated with this Center:

  • Dr. Robert F. Spiera, Director
  • Dr. Jessica Gordon
  • Dr. Lindsay Lally
  • Dr. David Fernandez

Appointments: Ebony Jackson (212) 606-1173; Dorcas Mcrae (212) 774-2434

Physician Inquiries: Dr. Robert Spiera (212) 774-2048; Dr. Jessica Gordon (212) 606-1173; Dr. Lindsay Lally (212) 774-2434:Dr. David Fernandez (212) 606-1501

Research Information: Elizabeth Soto-Cardona, M.P.H., Center Manager (212) 774-2048
Beemnet Amdemicael (212) 774-2123 or Mosammed Kabir (212) 774-7194, Jesse Ojeda (212) 774-7620

Studies Status
Pulmonary Hypertension Assessment Registry of Scleroderma. A prospective observational longitudinal cohort study of patients with scleroderma who are at high risk for pulmonary hypertension. (PHAROS) Completed
A prospective, observational, longitudinal database that will store clinical information and biological materials to facilitate basic scientific research and clinical studies of patients with scleroderma.(HSS SCLERODERMA REGISTRY) Active, recruiting
Prospective Registry of Early Systemic Sclerosis (PRESS)

This registry aims to better understand early diffuse systemic sclerosis by capturing clinical data, basic science markers, and candidate genes from patients. All patients that were diagnosed with diffuse scleroderma in the past two years and are 18 years or older are eligible to be enrolled in this registry. Study visits will occur approximately every 6 months and will involve questionnaires, a physical examination, and blood draws for research purposes.

Active

A Phase 1 Open-Labeled Study to Determine the Safety and Tolerability of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients with Diffuse Cutaneous Systemic Sclerosis

This Phase 1 study seeks to evaluate the safety and tolerability of sequential escalating doses of AVID200 administered once every 2 weeks (Q2W) by 1-hour intravenous (IV) infusion to patients with diffuse cutaneous systemic sclerosis (dcSSc). We will identify a potential effective range of tolerated doses to be further evaluated in a future Phase 2 trial
Actively Recruiting

Contact:
Beemnet Amdemicael
(212) 774-2123
A Randomized, Double-Blind, Placebo-Controlled Study of Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

This is a randomized, double-blind, placebo-controlled study to assess efficacy of Rituximab and Belimumab combination therapy in patients with diffuse cutaneous Systemic sclerosis (SSc, Scleroderma).
Actively recruiting

Contact:
Beemnet Amdemicael 
(212) 774-2123
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects with Symptomatic Raynaud’s Phenomenon Secondary to Systemic Sclerosis

This is a study that seeks to evaluate the efficacy of Iloprost compared to placebo on the change in the weekly frequency of symptomatic RP attacks from baseline in subjects with symptomatic RP secondary to SSc.
Actively Recruiting

Contact:
Beemnet Amdemicael
(212) 774-7194
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

The objective of this study is to assess the efficacy and safety of Lenabasum (formerly Anabasum, formerly JBT101). Lenabasum is a novel synthetic selective oral agonist of cannabinoid receptor type 2 that activates resolution of innate immune responses. This is a multicenter, double-blind, randomized; placebo-controlled, parallel group assessment of efficacy and safety of 52 weeks of treatment with Lenabasum in diffuse cutaneous SSc. Patients will be randomized 2:1 favoring two different doses of active treatment. Lenabasum is administered orally and is taken twice a day.
Currently Enrolling

Contact:
Jesse Ojeda
(212) 774-7620
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (BRAVOS)

The objective of this study is to evaluate the safety and tolerability of intravenous Brentuximab Vedotin. This trial will be conducted as a multicenter prospective double blind placebo controlled dose escalation safety study with Brentuximab Vedotin and stable background immunosuppressive therapy in adult individuals with dcSSc. Eligible participants will be randomly assigned to study treatment, either Brentuximab Vedotin or placebo equivalent in a 6:2 ratio favoring Brentuximab Vedotin. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
Currently Enrolling

Contact:
Anna Yusov
(212) 774-7620
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Cutaneous Systemic Sclerosis or Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Ifetroban is a-well characterized pharmacological antagonist of the Thromboxane Prostanoid (TP) Receptor (TPr). This placebo-controlled study will explore Ifetroban in patients with diffuse cutaneous scleroderma (dcSSc) or scleroderma associated pulmonary arterial hypertension (SSc-PAH). The multicenter study will enroll a total of 5 patients at HSS. Patients will be stratified based upon their clinical presentation of accompanying pulmonary arterial hypertension. There will be a 365 day blinded treatment in this study.
Currently Enrolling

Contact:
Alexandra Morquette
(212) 774-7194
Scleroderma Lung Study III (SLS III): Combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related interstitial lung disease

The objective of this study is to assess the relative efficacy and safety of combining two drugs with different mechanisms of action, Pirfenidone and mycophenolate, as compared to treatment with mycophenolate alone, for the treatment of scleroderma-related interstitial lung disease.  This is a phase II, multi-center, randomized, double-blinded, placebo-controlled trial. Patients will be randomized 1:1 to placebo and mycophenolate or Pirfenidone and mycophenolate for a 18-month randomization period with a 1 month follow up period. A total of 150 patients will be enrolled in the study across all sites.
Currently Enrolling

Contact:
Annel Fernandez
(212) 774-2123

 

nyc columbia center.jpgColumbia University Medical Center/
New York-Presbyterian Hospital Scleroderma Program

Herbert Irving Pavilion, 2nd Floor
161 Fort Washington Avenue
New York, NY  10032

Telephone:  (212) 305-4308
Fax:  (212) 304-6610

Program Director:  Elana J. Bernstein, M.D., M.Sc.

Research coordinator:  Rachel Broderick, M.S.
Telephone:  (212) 342-2713
Email: rb3173@cumc.columbia.edu

Clinic information:  Adult and pediatric patients with systemic and localized scleroderma
Hours:  Monday through Friday, 9 a.m. to 5 p.m.
Appointments:  (212) 305-4308
Physician inquiries:  (212) 305-4308
Research inquiries:  (212) 342-2751
http://rheumatologyatcolumbia.org/

Physicians Affiliated with this Center:

  • Rheumatology:  Elana J. Bernstein, M.D., M.Sc.
  • Pediatric Rheumatology:  Lisa Imundo, M.D.
  • Pulmonology/Interstitial Lung Disease:  Nina Patel, M.D., and David Lederer, M.D., M.S.
  • Pulmonology/Lung Transplantation:  Selim Arcasoy, M.D.
  • Pulmonary Hypertension/Cardiology:  Erika Berman-Rosenzweig, M.D., and Jennifer Haythe, M.D.
  • Dermatology:  Stephanie Gallitano, M.D.
  • Pediatric Dermatology:  Maria C. Garzon, M.D., Kimberly Morel, M.D., and Christine Lauren, M.D.
  • Gastroenterology:  Daniela Jodorkovsky, M.D., David D. Markowitz, M.D.
  • Medical Nutrition:  David S. Seres, M.D., Sc.M., P.N.S.
Studies Status
Prospective Registry of Early Systemic Sclerosis (PRESS), Phenotypic, Serologic, and Biomarker/Genetic Characteristics of Early Diffuse Cutaneous Systemic Sclerosis Active, Recruiting
COllaborative, National QUality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (Scleroderma Patients) (CONQUER) Active, Recruiting
Scleroderma Biobank Active, Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis Active, Recruiting
Genome Research in African American Scleroderma Patients (GRASP) Active, Recruiting
Screening High Resolution Computed Tomography Scan of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis (SScREEN ILD) Active, Recruiting
Validation of the preliminary Assessment of Scleroderma associated RAynaud's Phenomenon (ASRAP) questionaire Active, Recruiting

Back to top


North Carolina

Durham

Duke Scleroderma CenterDuke Health
Duke Clinic IJ, Durham, NC 27710

As one of the nation’s leading rheumatology centers, Duke specializes in diagnosing and treating scleroderma. Additionally, Duke is one of the few centers in the nation to offer stem cell transplantation as part of your treatment for scleroderma. We are located in Durham, NC.

To learn more about scleroderma treatment options at Duke, please visit us at:
www.dukemedicine.org/treatments/inflammatory-and-immune-disorders/scleroderma

To learn more bone marrow transplant or stem cell transplant as an option for scleroderma, please visit us at: https://www.dukehealth.org/treatments/cancer/adult-bone-marrow-transplant

Clinic Information: Adult and pediatric patients seen with systemic scleroderma.
Hours: 8 a.m. to 5 p.m. Monday through Friday.
Duke also has a Pulmonary Vascular Disease Clinic.

Physicians Affiliated with this Center:

  • Ankoor Shah, M.D. (Rheumatology)
  • Terry Fortin, M.D. (Pulmonary Hypertension)
  • Lake Morrison, M.D. (Pulmonary Fibrosis)
  • Rahul Shimpi, M.D. (Gastroenterology)
  • Rambi Cardones, M.D. (Dermatology)
  • Gwynn Long, M.D. (Cellular Therapy/Stem Cell Transplant)

For appointments in our Rheumatology Clinic at Duke: (919) 684-4499

For appointments in our Adult Blood & Marrow Transplant Clinic at Duke: (919) 684-8964

Physicians Inquiries and Research information: Ankoor Shah, MD (919) 684-4499

Study

Description

Recruitment Status

BRAVOS

Phase I study of brentuximab vedotin in patients with early diffuse cutaneous systemic sclerosis

Active, Recruiting

Scleroderma Registry

Ongoing clinical registry of patients with systemic sclerosis

Active, Recruiting

Affinergy

Using phage display technology, we are looking at discovering new antibodies to aid in diagnosis and prognosis in systemic sclerosis

Active, Recruiting

CATALYST

A phase II/III study of bardoxolone methyl in patients with pulmonary hypertension associated with connective tissue disease

Active, Recruiting

SENSCIS

Phase III study of nintedanib in the treatment of systemic sclerosis related interstitial lung disease

Active, Closed to Recruitment

Back to top


Ohio

Columbus

Ohio State University Wexner Medical Center,
Martha Moorehouse Clinic
2050 Kenny Rd., Ste. 2200, Columbus, OH 43221
(614) 293-4837
8 a.m. - 12 Noon, Monday mornings
Adult patients only

Physicians Affiliated with this Center:

  • Vascular: Steven Dean, M.D.
  • Gastrointestinal: Jon Walker, M.D.
  • Pulmonary: Nitin Bhatt, M.D., Veronica Franco, M.D., Jimmy Smith, M.D.
  • Dermatology: Benjamin Kaffenberger, M.D.

Research Information:

Studies Status
Ohio State University Scleroderma Registry
A Randomized, Double-blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) (Protocol # ASC01)
Recruiting

 

Cincinnati

University of Cincinnati Medical Center  –
Scleroderma Clinic now at 2 locations for patient's convenience
Locations 1-3590 Lucille Dr Ste 2700, Cincinnati, OH 45213
Location 2-7798 Discovery Dr Ste F, West Chester, OH 45069
Scheduler- Tammy Baker.
Phone: (513) 475-8523

Physicians Affiliated with this Center:

Rheumatology
Dr. Surabhi A. Khanna
Pulmonary
Interstitial lung disease (ILD)

Dr. Nishant Gupta
Dr. Frank McCormack
Dr. Gaurav Khanna

Pulmonary Hypertension
Dr. Jean Elwing 

Gastroenterology
Dr. Vidhya Kunnathur 

Nephrology
Dr. Suresh Kamath 

Chest Radiologist
Dr. Sangita Kapur 

Chest Pathologist
Dr. Dani Zander
Dr. Kathryn Wikenheiser-Brokamp 

Basic research
Dr. Satish Madala 

Research Coordinator
Rebecca Ingledue

Research Information:

Studies Status
Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD). Accepting patients
Pulmonary Arterial Hypertension Clinical Trials Multiple clinical trial and registry opportunities are available.

Please contact UC Pulmonary Hypertension Research Team to review opportunities.

UC Pulmonary Hypertension Research Coordinator:  Emilee Orr, RN, (513) 558-3077

UC Pulmonary Research Manager:  Tammy Roads, (513) 558-2148

 

Cleveland

Cleveland Clinic
9500 Euclid Avenue
Cleveland, Ohio 44195
(216) 444-2200

Cleveland Clinic’s Scleroderma Program is dedicated to helping patients and their families who are affected by scleroderma.  Established under the leadership of Soumya Chatterjee, M.D., it includes a multidisciplinary clinic so that patients can seamlessly receive all the care that they need.  Our program’s goals are to help patients best control their disease and improve their quality of life.  Our treatment approach involves patient-customized treatment plans, including rheumatologists, pediatric rheumatologists, pulmonologists, gastroenterologists, dermatologists, cardiologists as well as others, as needed.  Cleveland Clinic is actively engaged in research that seeks to understand how the disease begins and develops in hopes of developing innovative new treatments.  Children with scleroderma are seen by specially trained pediatric rheumatologists at Cleveland Clinic Children’s, who collaborate with our adult care team as needed to ensure the best outcomes for young patients.

Appointments:  (216) 444-2273
Research Inquiries:  (216) 445-6988

Clinic Hours:  Monday-Friday 8 a.m. 5 p.m.

Physicians Involved:

Studies

Status

Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis NCT03398837

Active, recruiting

Efficacy and safety of SAR156597 in the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc): A randomized, double-blind, placebo- controlled, 24-week, proof of concept study. STUDY NUMBER: ACT14604 NCT02921971

Active, not recruiting

A double blind, randomised, placebo- controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with

‘Systemic Sclerosis associated

Interstitial Lung Disease’(SSc-ILD).

NCT02597933

Active, not recruiting

A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension/CATALYST NCT02657356

Active, recruiting

An open-label extension trial to assess the long term safety of Nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD) NCT03313180

Active, recruiting

 

Toledo

University of Toledo Scleroderma Program
The Ruppert Center at University of Toledo Health Center Campus
3120 Glendale Ave., 1st floor
Toledo, Ohio 43614
Phone: (419) 383-4271
Fax: (419) 383-6244

Appointments: (419) 383-3627

Clinic Information: Adult, adolescent and pediatric patients with systemic and localized scleroderma are seen within one week of requested appointment. The center’s hours are between 9:00 a.m. and 5:00 p.m. Monday through Friday.

Professionals Affiliated with this Center:

  • Bashar Kahaleh, M.D. Rheumatology
  • Nezam Altorok M.D., Rheumatology
  • Rujuta Trivedi, M.D., Rheumatology
  • Navya Parsa, M.D., Rheumatology
  • Samer Khouri, M.D., Cardiology, Pulmonary Hypertension
  • Fadi Safi, M.D., Pulmonary Interstitial Lung Disease
  • Ali Nawras, M.D., Gastroenterology, Motility Disorder
  • Martin C. Skie, M.D, Orthopedics: Hand and Microsurgery
  • Deepak Maholtra, M.D., Ph.D., Nephrology
  • Yongqing Wang, Ph.D., Basic Research
  • Shadia Nada, Ph.D., Basic Research
  • Jennifer Gilmore, R.N., Research Coordinator
  • Oralia Hensley, Administrative Assistant, Oralia.Hensley@utoledo.edu

The center was established in 1992. Currently, we follow approximately 130 SSc patients who are evaluated on a regular basis. The core physicians affiliated with the center cover all facets of care needed in scleroderma. Over the years, the center was involved in most of the major national and international clinical trials in SSc. Currently, we are involved in the following studies:

Studies

Status

Role of vasopressin in scleroderma pathogenesis

Active

Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program.

Active

The Effects of Pomalidomide, CC-220 and CC-122 on Scleroderma Vascular and Fibrotic Disorders.

Active

Epigenetic modification of endothelial and fibroblast gene expression in scleroderma.

Active

Randomized Open Label Phase II/III Multicenter of High Dose Immunosuppressive Therapy (SCOT)

Closed

A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects with Diffuse Cutaneous Systemic Sclerosis with Interstitial Lung Disease.

Closed

Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of Macitentan in patients with ischemic digital ulcers associated with systemic sclerosis.

Closed

A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis.

Closed

Educational Activities

The center has been active with the Scleroderma Foundation Ohio Chapter. We participate regularly in speaking engagements at patient support group’s meetings, co-organize annual walk for cure fundraiser and provide CME talks on topics related to scleroderma at the University of Toledo and the various hospitals in NW Ohio. Moreover, members presented abstracts and posters related to scleroderma regularly at the ACR, Scleroderma research workshops and world scleroderma congress meetings.

Back to top


Pennsylvania

Philadelphia

Scleroderma Center Listing_TJU pic.jpgThe Scleroderma Center of Thomas Jefferson University
211 South 9th Street Suite 600, Philadelphia, PA  19107
(Clinical Offices)
Suite 509, Bluemle Life Sciences Building
(Research Laboratories)
Appointments: (215) 955-8430*
Physician Inquiries: (215) 503-5042; (215) 955-2820
Research Inquiries: (215)-955-8405
*If an earlier appointment is needed please talk with our office manager, Elizabeth.

Main number: (215) 955-8430 (option 1) 

Physician Inquiries: (215) 503-5042; (215) 955-2820
Research Inquiries: (215) 955-8405
*If an earlier appointment is needed please talk with our office manager, Elizabeth.

Sergio A. Jimenez, M.D., M.A.C.R., Director
Fabian A. Mendoza, M.D., F.A.C.R., Associate Director
Marsha Simmons RN; Research Coordinator

Physicians Affiliated with this Center:

Rheumatology: 215-955-8430

  • Fabian A Mendoza, M.D., F.A.C.R.

Gastroenterology:

  • Sidney Cohen, M.D.
  • Anthony J. DiMarino, Jr., M.D.

Pulmonary Medicine/Pulmonary Hypertension

  • Sandra B. Weibel, M.D.
  • Michael Scharf, M.D.

Cardiology:

  • Albert N. Brest, M.D.
  • Philip Nimoityn, M.D.
  • Howard H. Weitz, M.D.

Dermatology:

  • Jason Lee, M.D
  • Mathew Keller, M.D.

Dermatopathology:

  • Jason Lee, M.D

Dental Surgery:

  • Niles Nicolo, D.D.S.

 

Hand Surgery:

 

  • Lee A. Osterman, M.D.

 

Studies

Status

Nintedanib versus placebo in Systemic Sclerosis associated interstitial lung disease. Active. Not enrrolling
A prospective observational study of mycophenolate treatment for Scleroderma. Actively enrolling
Tocilizumab vs Placebo in patients with Systemic Sclerosis (Phase III) Completed. Not enrolling
Immune Cellular and Molecular Mechanisms in Systemic Sclerosis (Scleroderma) Actively enrolling
Development and Analysis of a Comprehensive Clinical and Laboratory Data Collection on Patients With Sclerosing Diseases Actively enrolling
The Identification of Novel Markers for Systemic Sclerosis Employing Proteomics Actively enrolling
Stratification of Symptoms and Evaluation of the Presence and Quantification of Autoantibodies in Patients with Diffuse and Limited Scleroderma Actively enrolling
Elucidating the role of non-coding RNAs in MS and SSc Actively enrolling
Role of microRNA in the pathogenesis of Tissue Fibrosis and Vasculopathy in SSc Actively enrolling
Functional Anti-muscarinic Antibodies: A Possible Etiology for Gastrointestinal Dysmotility in Scleroderma Actively enrolling

 

 

Philadelphia

Penn Scleroderma Center

Locations:

University of Pennsylvania
Perelman Center for Advanced Medicine
South Pavilion, First Floor
3400 Civic Center Boulevard
Philadelphia, PA  19104

Penn Medicine Radnor
250 King of Prussia Road
Radnor, PA  19087 

Penn Medicine Valley Forge
1001 Chesterbrook Boulevard
Berwyn, PA  19312

Physicians Affiliated with this Center:

  • Peter Merkel, M.D., M.P.H.
  • Chris Derk, M.D.
  • Nora Sandorfi, M.D.
  • Colin Ligon, M.D., M.H.S.

For appointments, call (800) 789-7366; Fax: (215) 349-5703

Research Inquiries: rheumatologyresearch@uphs.upenn.edu

Studies

Status
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial Study to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis Recruitment Completed
Genome Research in African American Scleroderma Patients (GRASP) Study Actively Recruiting
Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200, a Transforming Growth Factor β  Inhibitor, in Patients with Diffuse Cutaneous Systemic Sclerosis Actively Recruiting
National Quality and Efficacy Registry for Tracking Disease Progression in Patients with Systemic Sclerosis (CONQUER) Actively Recruiting
Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes Open September 2020
Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen®) for the Treatment of Adults with Systemic Sclerosis Open May 2020

 

Pittsburgh

Presby.jpgUPMC & University of Pittsburgh, Arthritis and Autoimmunity Center
Falk Medical Building, Suite 2B
3601 Fifth Avenue
Pittsburgh PA 15213
Visit website

Clinic Information: Adult patients seen with localized and systemic scleroderma or Raynaud Disease. Hours: 8 a.m. to 5 p.m., Monday through Friday.

Faculty Affiliated with this Center:

  • Robert Lafyatis, M.D., Director
  • Robyn T. Domsic, M.D., M.P.H.

New Patient Appointments: (412) 864-7055

Return Patient Appointments: (412) 647-6700

Specialists:

  • Pulmonary Arterial Hypertension:  Drs. David Ishizawar, Marc Simon, Michael Mathier, Gavin Hickey at the Pulmonary Hypertension Clinic (877) 744-8762
  • ILD:  Drs. Kevin Gibson, Daniel Kass, Kristen Veraldi, Jared Chiachiaro at the Simmons ILD Center (412) 648-6161
  • GI:  Drs. Klaus Bielefeldt, Kenneth Fasanella at the Center for Digestive Diseases (412) 647-8666
  • Motility/Upper GI/Malnutrition: Dr. Klaus Bielefeldt at the Center for Digestive Diseases (412) 647-8666
  • Renal Crisis:  Dr. Kevin Ho at the UPMC Kidney Clinic (412) 802-3043


Research Information: Krist Kong (412) 648-7040 or Maureen Laffoon (412) 648-7871

Studies

Status

Banking of Biological Samples and Collection of Clinical Data for Connective Tissue Disease Research

Actively Recruiting

Scleroderma Lung Study III (SLS III): Combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma related interstitial lung disease (SSc-ILD)

Actively Recruiting

AVID200 Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200 in Diffuse Cutaneous Systemic Sclerosis

Actively Recruiting

 

University of Pittsburgh Children's Hospital

UPMC & University of Pittsburgh, Children’s Hospital of Pittsburgh,
Pediatric Rheumatology Department

One Children's Hospital Way
4401 Penn Avenue, Pittsburgh, PA 15224 (Clinical Offices)
http://www.chp.edu/CHP/rheumatology

Clinic Information: Pediatric patients seen with localized and systemic scleroderma.
Hours: 8 a.m. to 5 p.m. Monday through Friday.

Kathryn S. Torok, M.D., Director
Kaila Schollaert-Fitch, M.A., Clinical Research Coordinator
Emily Mirizio, Research Technician

Appointments: (412) 692-5081
Research Inquiries: (412) 692-6478 scleroderma@chp.edu

Physicians affiliated with this center:

Rheumatology:

  • Kathryn Torok, M.D.
  • Margalit Rosenkranz, M.D.
  • Daniel Kietz, M.D.
  • Elaine Cassidy, M.D.
  • Abbe de Vallejo, Ph.D.

 

Studies

Status

National Registry for Childhood Onset Scleroderma

Actively Recruiting

Development of Clinical Disease Outcome Measures with Biological Sub-studies for Localized Scleroderma (LOCUS-2)

Closed to Enrollment/In Data Analysis 

Observational Study for Pediatric Rheumatic Diseases: The CARRA Registry

Actively Recruiting

Scleroderma Collaborative Research Grant (SCORE): Identifying juvenile scleroderma immunophenotype subsets. A CARRA pilot study

Enrollment begins March 2019

Prospective Analysis of Skin Biopsies in Localized Scleroderma

Actively Recruiting

Inceptions Cohort for Juvenile Systemic Sclerosis (jSSc)

Actively Recruiting

Immunopathogenesis of Pediatric Rheumatic Diseases

Actively Recruiting

Localized Scleroderma Cutaneous Assessment Tool: Collection of Clinical Disease Scores

Closed to Enrollment/In Data Analysis

Development of Clinical Disease Activity Measures for Pediatric Localized Scleroderma

Closed to Enrollment/In Data Analysis

Quality of Life in Pediatric Localized Scleroderma

Closed to Enrollment/In Data Analysis

Back to top


South Carolina

Medical University of South Carolina Scleroderma CenterCharleston

Medical University of South Carolina
96 Jonathan Lucas Street
Charleston, SC 29425

Appointments: (843) 792-9200
Physician Inquiries: Richard M. Silver, M.D., (843) 792-3484 

Research Inquiries: (843) 792-3484
Richard M. Silver, M.D.
Carol Feghali-Bostwick, Ph.D.

Physicians Affiliated with this Center:

Rheumatology:

  • Richard M. Silver, M.D.
  • Edwin A. Smith, M.D.
  • Faye Hant, D.O., M.S.C.R.
  • Aiken McNair, P.A.
  • Celine Ward, M.D.
  • Katherine Silver, M.D., M.S.C.R.
  • DeAnna Baker Frost, M.D., Ph.D.

Gastroenterology:

  • Pooja S. Elias, M.D.

Pulmonary Medicine/Pulmonary Hypertension:

  • J. Terrill Huggins, M.D.
  • Rachana Krishna, M.D.
  • Rahul Argula, M.D.

Cardiology:

  • Ryan Tedford, M.D.

Dermatology/Dermatopathology:

  • Richard M. Marchell, M.D.
  • Laura Winterfield, M.D.

Dental Surgery:

  • Michele Ravenel, D.M.D.

Hand Surgery:

  • M. Lance Tavana, M.D.

 

Studies Status
Efficacy and Safety of Riociguat in Patients with Systemic Sclerosis Filled
Care Center for Clinical Research, CCCR (P30) Recruiting
Prospective Registry of Early Systemic Sclerosis, (PRESS) Phenotypic, Serologic, and Biomarker/Genetic Characteristics of Early Diffuse Cutaneous Systemic Sclerosis Recruiting
Safety and Suitability of Dabigatran to Inhibit Thrombin in Systemic Sclerosis Recruiting
Scleroderma Lung Study Recruiting
Cumberland Ifetroban Study Recruiting
BRAVOS Study Recruiting

Back to top


Tennessee

University of Tennessee Scleroderma CenterMemphis

University of Tennessee Health Science Center
956 Court Avenue, Room G326, Memphis, TN 38163
Phone: (901) 448-5774 (Academic Office)
www.uthsc.edu

 
 
Debendra Pattanaik, M.D. 
Syed Raza, M.D. 
Bradley Postlethwaite, M.D.
Vaishnavi Pulusani, M.D.
Linda Myers, M.D. (Pediatric only)
Monica Brown, M.D. (Pediatric only)

 
 
 
Clinical Practice

 
 
University Methodist Medical Practice
1211 Union Avenue, Ste. 200, Memphis, TN 38104
(901) 525-0278 - Appointments
 
Debendra Pattanaik, M.D.
Titilioa Akhigbe, M.D. 

 
 
Regional One Health – (Medplex)
880 Madison, Ste. 4E01, Memphis, TN 38103
 
 
(901) 545-6969 - Appointments
Syed Raza, M.D. 
 
 

UT Regional One Health 
6555 Quince Rd., Memphis, TN 38119
 
 
(901) 515-3150 - Appointments
Syed Raza, M.D.
 
 

University Clinical Health
6401 Poplar Avenue, Ste. 190, Memphis, TN 38119
 
 
(901) 866-8700 – Appointments
Bradley Postlethwaite, M.D. 
Vaishnavi Pulusani, M.D. 
 
 
 

LeBonheur Children’s Hospital
(901) 287-7337 – Appointments
Linda Myers, M.D. (Pediatric only)
Monica Brown, DO (Pediatric only) 
 
 

Our physicians specialize in all connective tissue diseases with emphasis on scleroderma, rheumatoid arthritis, and systemic lupus erythematosus.
 
 

Current Research
 
Dr. Debendra Pattanaik:  Systemic Lupus Erythematosus.

Rheumatoid Arthritis, Systemic Sclerosis, Vitamin D in Rheumatoid Arthritis
 
 

For specific information regarding studies please call (901) 448-5774.

 

Back to top


Texas

University of Texas Houston Scleroderma CenterHouston

University of Texas Scleroderma Clinic
Frank C. Arnett Center for Autoimmunity
6410 Fannin, Suite 450, Houston, TX 77030
https://www.utphysicians.com/specialty/rheumatology/

Clinic Information: Adult, systemic, diffuse and limited scleroderma. Call office for hours

Clinic Hours
Monday - Friday 8 a.m. - 5 p.m.

Clinic Appointments: (713) 486-3100
Clinic Fax: (713) 512-2246


Participating Physicians:

  • Maureen Mayes, M.D., M.P.H.
  • Shervin Assassi, M.D., M.S.
  • Brian Skaug, M.D., Ph.D.

Research Information Contacts: Patricia Gonzales, LVN, (713) 500-7118 and Samuel Theodore (713) 500-6859

 

Studies

Status

ACT 145604(Sanofi)

Active, enrolling

GENISOS (Longitudinal Study of Early Scleroderma)

Active, enrolling

Scleroderma Family Registry and DNA Repository

Active, enrolling

RESOLVE (Corbus)

Active, enrolling

BRAVOS (Immune Tolerance Network through the University of Michigan and NIH)

Active, enrolling

ASC01 – Rituximab in SSc-Pulmonary Arterial Hypertension

Active, enrolling

STAT study – Stem Cell Transplant study in early diffuse scleroderma

Active, enrolling

Scleroderma Lung Study III (SLS III)- NIH through UCLA

Active, enrolling

Senscis Study – early SSc lung disease

Active, filled

CATALYST (Reata) – Pulmonary hypertension in SSc

Active, enrolling

Back to top


Washington

 

Seattle

 

Seattle Children’s Hospital
Rheumatology Clinic
MA 7.110
4800 Sand Point Way NE
Seattle, WA  98105 

 

http://www.seattlechildrens.org/clinics-programs/rheumatology/

 

Clinic Information: Pediatric, systemic, localized. Call office for hours

Clinic Hours
Monday - Friday 8:00 AM – 5:00 PM

Appointments: (206) 987-2057

Participating Physicians:

 

  • Anne M. Stevens, MD, PhD (Rheumatology)
  • Sarah Ringold, MD (Rheumatology)
  • Demet Toprak, MD (Pulmonology))
  • Ramesh Iyer, MD (Radiology)
  • Margaret Rosenfeld, MD (Pulmonology)
  • Heather Brandling-Bennett, MD (Dermatology)
  • Lusine Ambartsumyan, MD (Gastroenterology)
  • Paul Carpenter, MD (Hematology/Oncology)
  • Gail Deutsch, MD (Pathology)

 

Research Information Contacts: Lucas Reichley (206) 987-3253

 

Studies Status
Genetic Associations in Juvenile Systemic Sclerosis Recruiting
Early detection of SSc interstitial lung disease. Active, not recruiting
Treatment of early jSSc pulmonary fibrosis. Active, not recruiting
Stem cell transplantation for refractory jSSc. Recruiting
Classification and Outcomes Measures for jSSc. Active, not recruiting
CARRA Registry for jSSc and Localized SSc (SCORE) - Active recruiting

 

 

 

Seattle scleroderma centerVirginia Mason Medical Center
6th floor of Lindeman Building, 1100 9th Ave., Seattle, WA 98101
www.benaroyaresearch.org

 

Clinic Information: Patients seen with systemic and localized scleroderma. 8 a.m. to 5:30 p.m. Monday through Friday.

 

For appointments: (206) 223-6824
For MD calls: (206) 223-6668

 

Physicians Affiliated with this Center:

 

  • Jane Buckner, M.D.
  • Jeff Carlin, M.D.
  • Erin Bauer, M.D.
  • Amish Dave, M.D.
  • Elizabeth Jernsberg, M.D.
  • Meredith Morcos, M.D.
  • Vivian Stone, M.D..
  • Su Yin, M.D.

 

All scleroderma trials at Virginia Mason are currently on hold, please call (206) 223-6824 for more information. 

 

For more information on studies: https://www.benaroyaresearch.org/our-research/clinical-research/currently-enrolling-studies

 

     

The Scleroderma Clinic at the University of Washington
4245 Roosevelt Way NE 2nd floor
Seattle, WA  98105

Physicians Affiliated with this Center:

  • Mark Wener, M.D.
  • Ganesh Raghu, M.D.

Clinic information: Referrals to the Scleroderma Clinic for consultation and/or management can be made by calling (206) 598-6285; or fax (206) 598-5646.


Back to top


Wisconsin

Milwaukee

Medical College of Wisconsin/Froedtert Hospital
Medical College of Wisconsin - HUB 8th Floor
Department of Medicine/Rheumatology
8701 Watertown Plank Road
Milwaukee, WI  53226

Froedtert Specialty Clinics Building
Rheumatology Clinic - 4th Floor
9200 West Wisconsin Avenue
Milwaukee, WI  53226

Appointment scheduling (by physician referral only):  (414) 805-6633

New scleroderma patient evaluations on Wednesday afternoons.
All forms of scleroderma treated (adult patients only; Pediatric evaluation on referral from Rheumatologist)

Additional questions can be directed to Dr. Csuka’s Administrative Assistant, Karen Roberts at (414) 955-7027, or Jesa Landis, M.D., Clinical Research Coordinator I, (414) 805-8105, jlandis@mcw.edu.

Physician affiliated with this center:
Mary Ellen Csuka, M.D.
Professor of Medicine

Research Information:
John Osicky, B.A. - Research Assistant, (414) 805-5498, josicky@mcw.edu
Jesa Landis, M.D., Clinical Research Coordinator I, (414) 805-8105, jlandis@mcw.edu

 

Studies Status
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis Open to Enrollment
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes Closed

 

Back to top